Clinical Trials Logo

Filter by:
NCT ID: NCT00043927 Completed - Clinical trials for Small Cell Lung Cancer

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Start date: April 2001
Phase: Phase 3
Study type: Interventional

This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.

NCT ID: NCT00040183 Completed - Pancreatic Cancer Clinical Trials

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Start date: November 29, 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.

NCT ID: NCT00038103 Completed - Breast Neoplasms Clinical Trials

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Start date: January 2002
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.

NCT ID: NCT00037791 Completed - Multiple Myeloma Clinical Trials

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Start date: December 1999
Phase: Phase 3
Study type: Interventional

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of this investigational drug in the prevention of thrombocytopenia in patients with solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support.

NCT ID: NCT00036647 Completed - Clinical trials for Carcinoma, Non-small-cell Lung

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Start date: November 1, 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).

NCT ID: NCT00036218 Completed - Parkinson Disease Clinical Trials

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

Start date: December 2001
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.

NCT ID: NCT00036088 Completed - Schizophrenia Clinical Trials

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Start date: August 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

NCT ID: NCT00035425 Completed - Febrile Neutropenia Clinical Trials

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Start date: November 2001
Phase: Phase 3
Study type: Interventional

This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).

NCT ID: NCT00035308 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.

NCT ID: NCT00034853 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

Start date: December 2000
Phase: Phase 3
Study type: Interventional

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)